Abeona Therapeutics ABEO 深 沪
等待开盘 03-26 09:30:00 美东时间
4.465
+0.135
+3.12%
华盛通- 最 高4.52
- 今 开4.35
- 成交量 64.08万股
- 最 低 4.35
- 昨 收 4.33
- 总市值 2.55亿
- 52周最高 7.5401
- 市盈率 静 4.40
- 换手率 1.12%
- 52周最低 3.9328
- 委 比 14.46%
- 总股本 5704.90万
- 历史最高 750.00
- 量 比 0.46
- 振 幅 3.93%
- 历史最低 2.19
- 每 手 1
- 风险率 0.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules
Abeona Therapeutics ( ($ABEO) ) has provided an announcement. On March 16, 2026...
03-21 05:07
Abeona Therapeutics Balances Big Windfall With Slow Ramp
Abeona Therapeutics Inc (($ABEO)) has held its Q4 earnings call. Read on for th...
03-18 08:15
Abeona Therapeutics 2025 net income slightly misses estimates on higher SG&A costs
Abeona Therapeutics 2025 net income slightly misses estimates on higher SG&A costs Overview US biopharma firm's 2025 net income slightly missed analyst expectations Income from operations missed analyst consensus, reflecting higher SG&A costs post-ZEVASKYN launch 2025 revenue reflects first ZEVASKYN
03-17 19:40
Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 4.49 percent. This is a 142.86 percent decrease over losses of $(0.14) per share
03-17 19:38
Abeona Therapeutics FY2025 SG&A expenses jumped 117.6% to USD 65.03 million
Abeona Therapeutics FY2025 SG&A expenses jumped 117.6% to USD 65.03 million Abeona published a press release reporting full-year 2025 financial results and corporate updates. Total revenue was USD 5.82 million, including USD 2.42 million in net product revenue from a single ZEVASKYN treatment and US
03-17 19:31
Earnings Scheduled For March 17, 2026
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is expected to ...
03-17 19:11
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
- First ZEVASKYN commercial patient treatment completed in December; launch momentum building in first quarter 2026 - Abeona reports $191.4M in cash, cash equivalents, and short-term investments as of December 31, 2025 - Total revenue for 2025 was $5.8M, including $2.4M in net product revenue from the first ZEVASKYN treatment - Net income for 2025 was $71.2M, compared to a net loss of $63.7M in 2024 - Cost of sales decreased significantly...
03-17 11:30
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
03-10 19:17
Abeona Therapeutics Inc. published an update to their financial calendar
Abeona Therapeutics Inc. published an update to their financial calendar Abeona Therapeutics Inc. will host a conference call on March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. A live, listen-only webcast and archived replay w
03-03 20:30
